Drug-resistant superbugs could cost up to $100 trillion and cause 10 million extra deaths a year by 2050

In a report published on the 11th December by the Review on Antimicrobial Resistance, set up by the UK Prime Minister David Cameron, it has been estimated that drug-resistant infections will cost the world 10 million extra deaths a year and up to $100 trillion by 2050, if the global increase is not stopped. Drug-resistant infections already kill hundreds of thousands of people globally every year, and the trend is growing. The analysis was produced by RAND and KPMG, with input from experts in the scientific community. Jim O’Neill, Chairman of the Review on AMR, said: “Drug-resistant infections already kill hundreds of thousands a year globally, and by 2050 that figure could be more than 10 million. The economic cost will also be significant, with the world economy being hit by up to $100 trillion by 2050 if we do not take action.” Dr Bill Love, CEO of Destiny Pharma said “The figures in this report, particularly the potential human cost of not addressing antibiotic resistance are quite frightening. Fortunately the report does make the case that this crisis can be averted if global action is taken soon to address this huge problem the report highlights just how great the need for new antimicrobial drugs is.”

Destiny Pharma invited to attend the first event of the Review on Antimicrobial Resistance Meeting chaired by Jim O’Neill and hosted by the Wellcome Trust on the 11th December 2014

Destiny Pharma have been invited to attend the first event for the Review on Antimicrobial Resistance which has been set up by David Cameron, the British Prime Minister to be held at the Wellcome Trust in London. Jim O’Neill, the chairman of the review, will present a paper looking at how much antimicrobial resistance could cost the world by 2050 if it is not tackled. The meeting will also discuss two questions with expert speakers, followed by an interactive discussion:

1. What will it take for new diagnostic technology to become reality? What policy changes are needed to change prescription practices and revolutionise the surveillance of diseases?

2. New antimicrobial drugs: How empty is the pipeline? Is the problem science or money?